Clinical trial
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine…
NCT00146744 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00146744 |
|---|---|
| Title | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults |
| Official title | Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tuberculosis (TB) |
| Intervention type | Biological |
| Interventions | Mtb72F/AS02A |
| Enrollment | 38 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 7, 2005 |
| Last update posted | May 30, 2017 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: